Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q1 2022 · 10-Q
Revenue—
Net Income-$37.17M-$37.17MN/M vs Q1 2021 EPS Diluted-$0.63-$0.63N/M vs Q1 2021 Operating Income-$36,858,000N/M Operating Cash Flow-$41,931,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end